Interchange Capital Partners LLC cut its holdings in shares of Exact Sciences Co. (NASDAQ:EXAS – Get Rating) by 6.7% during the 3rd quarter, Holdings Channel.com reports. The firm owned 9,022 shares of the medical research company's stock after selling 647 shares during the quarter. Interchange Capital Partners LLC's holdings in Exact Sciences were worth $293,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Steward Partners Investment Advisory LLC increased its holdings in shares of Exact Sciences by 44.4% in the 2nd quarter. Steward Partners Investment Advisory LLC now owns 667 shares of the medical research company's stock valued at $26,000 after acquiring an additional 205 shares during the last quarter. Northstar Group Inc. increased its holdings in shares of Exact Sciences by 4.9% in the 2nd quarter. Northstar Group Inc. now owns 5,346 shares of the medical research company's stock valued at $211,000 after acquiring an additional 250 shares during the last quarter. Panagora Asset Management Inc. increased its holdings in shares of Exact Sciences by 4.6% in the 1st quarter. Panagora Asset Management Inc. now owns 7,281 shares of the medical research company's stock valued at $509,000 after acquiring an additional 323 shares during the last quarter. Meiji Yasuda Life Insurance Co increased its holdings in shares of Exact Sciences by 5.0% in the 1st quarter. Meiji Yasuda Life Insurance Co now owns 6,895 shares of the medical research company's stock valued at $482,000 after acquiring an additional 326 shares during the last quarter. Finally, Banque Cantonale Vaudoise increased its holdings in shares of Exact Sciences by 7.9% in the 2nd quarter. Banque Cantonale Vaudoise now owns 4,626 shares of the medical research company's stock valued at $181,000 after acquiring an additional 339 shares during the last quarter. 90.30% of the stock is currently owned by hedge funds and other institutional investors.
Get
Exact Sciences alerts:
Insiders Place Their Bets
In other news, EVP Sarah Condella sold 1,000 shares of the business's stock in a transaction on Monday, January 9th. The stock was sold at an average price of $60.00, for a total value of $60,000.00. Following the sale, the executive vice president now owns 85,090 shares of the company's stock, valued at approximately $5,105,400. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.30% of the stock is currently owned by insiders.
Exact Sciences Stock Performance
EXAS stock traded up $2.44 during trading on Friday, reaching $67.48. 1,944,458 shares of the company's stock were exchanged, compared to its average volume of 3,110,676. The company has a quick ratio of 2.20, a current ratio of 2.47 and a debt-to-equity ratio of 0.72. Exact Sciences Co. has a 1-year low of $29.27 and a 1-year high of $84.31. The company's fifty day moving average price is $52.69 and its 200-day moving average price is $43.81. The firm has a market cap of $11.99 billion, a PE ratio of -16.46 and a beta of 1.30.
Exact Sciences (NASDAQ:EXAS – Get Rating) last announced its quarterly earnings results on Thursday, November 3rd. The medical research company reported ($0.84) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.10) by $0.26. Exact Sciences had a negative return on equity of 22.10% and a negative net margin of 35.73%. The company had revenue of $523.07 million during the quarter, compared to analyst estimates of $500.78 million. On average, research analysts expect that Exact Sciences Co. will post -3.67 EPS for the current fiscal year.
Analyst Ratings Changes
A number of equities research analysts have recently weighed in on EXAS shares. Robert W. Baird lowered their price target on Exact Sciences from $75.00 to $60.00 in a report on Friday, November 4th. StockNews.com started coverage on Exact Sciences in a report on Wednesday, October 12th. They issued a "hold" rating for the company. Craig Hallum boosted their price objective on Exact Sciences from $35.00 to $44.00 in a research report on Monday, January 9th. Piper Sandler boosted their price objective on Exact Sciences from $40.00 to $50.00 and gave the company a "neutral" rating in a research report on Monday, November 14th. Finally, BTIG Research reduced their price objective on Exact Sciences from $70.00 to $65.00 and set a "buy" rating for the company in a research report on Monday, November 7th. Six analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat.com, Exact Sciences presently has an average rating of "Moderate Buy" and an average price target of $61.57.
Exact Sciences Company Profile
(Get Rating)
EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI.
Further Reading
- Get a free copy of the StockNews.com research report on Exact Sciences (EXAS)
- MarketBeat Week in Review – 1/23- 1/27
- Why Lucid Spiked Nearly 100% In One Day
- Ride These Railroad Stocks for Growth and Income
- ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
- KLA Corporation: Strength In A Troubled Semi-Market
Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exact Sciences Co. (NASDAQ:EXAS – Get Rating).
Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
